{"transactions":[{"id":737902,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:18:17.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders."}],"balance_after":22100,"derivative":{"exercise_price":6.63,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001340881-26-000001","document":"wk-form4_1781569095.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000134088126000001/wk-form4_1781569095.xml","form_type":"4"}},{"id":745895,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T22:39:30.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date."}],"balance_after":40000,"derivative":{"exercise_price":10.55,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-262290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000119312526262290/ownership.xml","form_type":"4"}},{"id":747622,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:31:35.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":53250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":53250,"derivative":{"exercise_price":2.29,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":53250},"source":{"system":"sec-edgar","filing":"0001628280-26-041276","document":"wk-form4_1780691492.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000162828026041276/wk-form4_1780691492.xml","form_type":"4"}},{"id":747621,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:31:35.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":48300,"source":{"system":"sec-edgar","filing":"0001628280-26-041276","document":"wk-form4_1780691492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000162828026041276/wk-form4_1780691492.xml","form_type":"4"}},{"id":1095010,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:33:14.000Z","date":"2025-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. (\"TuHURA\"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA (\"Merger Sub I\"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA (\"Merger Sub II,\") and together with Merger Sub I, the \"Merger Subs\"), Kineta, Inc., a Delaware corporation (\"Kineta\") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the \"First Merger\"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the \"Surviving Corporation\"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the \"Second Merger\" and together with the First Merger, the \"Mergers\"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.58,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-093062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025093062/ownership.xml","form_type":"4"}},{"id":1095009,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T16:33:14.000Z","date":"2025-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13794,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. (\"TuHURA\"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA (\"Merger Sub I\"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA (\"Merger Sub II,\") and together with Merger Sub I, the \"Merger Subs\"), Kineta, Inc., a Delaware corporation (\"Kineta\") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the \"First Merger\"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the \"Surviving Corporation\"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the \"Second Merger\" and together with the First Merger, the \"Mergers\"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the First Merger (the \"Effective Time\"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share (\"Kineta Common Stock\"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share (\"TuHURA Common Stock\"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-093062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025093062/ownership.xml","form_type":"4"}},{"id":1101671,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T21:55:14.000Z","date":"2025-06-23","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the \"Company\") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation (\"TuHURA\"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025."}],"balance_after":0,"derivative":{"exercise_price":0.611,"expiration_date":"2034-09-03","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-25-090145","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025090145/ownership.xml","form_type":"4"}},{"id":1101670,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-25T21:55:14.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13794,"source":{"system":"sec-edgar","filing":"0000950170-25-090145","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025090145/ownership.xml","form_type":"4"}},{"id":1101669,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-25T21:55:14.000Z","date":"2025-06-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":4706,"price":0.26,"value":1223.56,"ownership":{"direct":true},"balance_after":7794,"source":{"system":"sec-edgar","filing":"0000950170-25-090145","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025090145/ownership.xml","form_type":"4"}},{"id":1101668,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-25T21:55:14.000Z","date":"2025-06-23","kind":"exercise","planned":false,"acquired":true,"shares":12500,"price":0.611,"value":7637.5,"ownership":{"direct":true},"balance_after":12500,"source":{"system":"sec-edgar","filing":"0000950170-25-090145","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025090145/ownership.xml","form_type":"4"}},{"id":1115129,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:46:36.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026."}],"balance_after":13500,"derivative":{"exercise_price":30,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001815776-25-000047","document":"wk-form4_1749678389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000047/wk-form4_1749678389.xml","form_type":"4"}},{"id":1121005,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:57:43.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":19500,"derivative":{"exercise_price":1.07,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001576885-25-000081","document":"wk-form4_1749156855.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000157688525000081/wk-form4_1749156855.xml","form_type":"4"}},{"id":1121004,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:57:43.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":12800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual\nstockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":12800,"source":{"system":"sec-edgar","filing":"0001576885-25-000081","document":"wk-form4_1749156855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000157688525000081/wk-form4_1749156855.xml","form_type":"4"}},{"id":1121003,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T20:14:20.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date."}],"balance_after":40000,"derivative":{"exercise_price":1.29,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-25-082335","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000095017025082335/ownership.xml","form_type":"4"}},{"id":1186115,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-01T20:21:03.000Z","date":"2025-03-28","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments from March 28, 2025 (the \"Vesting Commencement Date\") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service."}],"balance_after":80000,"derivative":{"exercise_price":1.28,"expiration_date":"2035-03-27","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-048555","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000095017025048555/ownership.xml","form_type":"4"}},{"id":1413794,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-05T16:19:48.000Z","date":"2024-09-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in equal quarterly installments over one year following June 21, 2024, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":0.611,"expiration_date":"2034-09-03","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-24-104013","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017024104013/ownership.xml","form_type":"4"}},{"id":1484599,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:40:12.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.62,"expiration_date":"2034-06-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001576885-24-000075","document":"wk-form4_1718052003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000157688524000075/wk-form4_1718052003.xml","form_type":"4"}},{"id":1561968,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:39:32.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 21, 2024."}],"balance_after":27000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001815776-24-000026","document":"wk-form4_1711413562.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000026/wk-form4_1711413562.xml","form_type":"4"}},{"id":1819329,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-02T00:09:31.000Z","date":"2023-07-28","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 28, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":40000,"derivative":{"exercise_price":2.52,"expiration_date":"2033-07-27","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-044075","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919123044075/doc4.xml","form_type":"4"}},{"id":1835989,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T16:18:40.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in equal quarterly installments over three years following July 1, 2023, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.58,"expiration_date":"2033-06-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-041031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000120919123041031/doc4.xml","form_type":"4"}},{"id":1863609,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-07T21:40:19.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.2,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001576885-23-000032","document":"wk-form4_1686174010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000157688523000032/wk-form4_1686174010.xml","form_type":"4"}},{"id":1904420,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.56,"underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904419,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":11.89,"underlying":"Common Stock","underlying_shares":44500},"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904418,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":53400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":6.55,"underlying":"Common Stock","underlying_shares":53400},"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904417,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":4.4,"underlying":"Common Stock","underlying_shares":44500},"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904416,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":97500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":23.98,"underlying":"Common Stock","underlying_shares":97500},"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904415,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":77235,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":9.56,"underlying":"Common Stock","underlying_shares":77235},"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904414,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8130,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":4.02,"underlying":"Common Stock","underlying_shares":8130},"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904413,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":206005,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":2.36,"underlying":"Common Stock","underlying_shares":206005},"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904412,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"other","planned":false,"acquired":false,"shares":40267,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes and (ii) one contingent value right."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes and (ii) one contingent value right."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":1904411,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-05-04T07:43:24.000Z","date":"2023-05-03","kind":"other","planned":false,"acquired":false,"shares":25751,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent (\"Merger Sub\"), dated as of March 26, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effectve as of May 3, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit settleable in Shares (each, a \"Company RSU\") vested in full, was cancelled and converted into the right to receive (i) the product of (A) the total number of Shares then underlying such Company RSU multiplied by (B) $1.85 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes and (ii) one contingent value right for each Share subject thereto."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit settleable in Shares (each, a \"Company RSU\") vested in full, was cancelled and converted into the right to receive (i) the product of (A) the total number of Shares then underlying such Company RSU multiplied by (B) $1.85 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes and (ii) one contingent value right for each Share subject thereto."}],"balance_after":40267,"source":{"system":"sec-edgar","filing":"0001640455-23-000107","document":"wf-form4_168320059150670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000107/wf-form4_168320059150670.xml","form_type":"4"}},{"id":2056469,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-01-11T20:30:22.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":7781,"price":1.12,"value":8714.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 7,781 shares sold in the price range of $1.05 to $1.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":66018,"source":{"system":"sec-edgar","filing":"0001640455-23-000009","document":"wf-form4_167348700319650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000009/wf-form4_167348700319650.xml","form_type":"4"}},{"id":2056468,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2023-01-11T20:30:22.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":6315,"price":1.1,"value":6946.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 6,315 shares sold in the price range of $1.03 to $1.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":73799,"source":{"system":"sec-edgar","filing":"0001640455-23-000009","document":"wf-form4_167348700319650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000009/wf-form4_167348700319650.xml","form_type":"4"}},{"id":2227129,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:22:45.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":3.59,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-037864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000120919122037864/doc4.xml","form_type":"4"}},{"id":2307505,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (right to buy)","published_at":"2022-04-04T21:11:12.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control."}],"balance_after":50000,"derivative":{"exercise_price":4.01,"expiration_date":"2032-04-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-022535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1340881/000120919122022535/doc4.xml","form_type":"4"}},{"id":2413975,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-03T19:38:04.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest quarterly in 16 equal installments following January 1, 2022."}],"balance_after":55000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001640455-22-000018","document":"wf-form4_164393506966078.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045522000018/wf-form4_164393506966078.xml","form_type":"4"}},{"id":2413974,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-02-03T19:38:04.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80114,"source":{"system":"sec-edgar","filing":"0001640455-22-000018","document":"wf-form4_164393506966078.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045522000018/wf-form4_164393506966078.xml","form_type":"4"}},{"id":2437746,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-01-11T20:56:21.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":8222,"price":6.65,"value":54676.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 8,222 shares sold in the price range of $6.57 to $6.90 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":52614,"source":{"system":"sec-edgar","filing":"0001640455-22-000009","document":"wf-form4_164195255982357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045522000009/wf-form4_164195255982357.xml","form_type":"4"}},{"id":2437745,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-01-11T20:56:21.000Z","date":"2022-01-07","kind":"sale","acquired":false,"shares":4595,"price":7.3,"value":33543.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 4,595 shares sold in the price range of $7.03 to $7.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":60836,"source":{"system":"sec-edgar","filing":"0001640455-22-000009","document":"wf-form4_164195255982357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045522000009/wf-form4_164195255982357.xml","form_type":"4"}},{"id":2680846,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:05:49.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":14800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021."}],"balance_after":14800,"derivative":{"exercise_price":15.26,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":14800},"source":{"system":"sec-edgar","filing":"0000899243-21-022018","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000089924321022018/doc4.xml","form_type":"4"}},{"id":2881859,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-03T17:46:47.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":44500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest quarterly in 16 equal installments following January 1, 2021."}],"balance_after":44500,"derivative":{"exercise_price":11.89,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":44500},"source":{"system":"sec-edgar","filing":"0001640455-21-000028","document":"wf-form4_161239239254752.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000028/wf-form4_161239239254752.xml","form_type":"4"}},{"id":2881858,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-02-03T17:46:47.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":22250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":65431,"source":{"system":"sec-edgar","filing":"0001640455-21-000028","document":"wf-form4_161239239254752.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000028/wf-form4_161239239254752.xml","form_type":"4"}},{"id":2899293,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-21","kind":"exercise","acquired":false,"shares":3799,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter."}],"balance_after":206005,"derivative":{"exercise_price":2.36,"expiration_date":"2025-08-25","underlying":"Common Stock","underlying_shares":3799},"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899292,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-20","kind":"exercise","acquired":false,"shares":3710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter."}],"balance_after":209804,"derivative":{"exercise_price":2.36,"expiration_date":"2025-08-25","underlying":"Common Stock","underlying_shares":3710},"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899291,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-20","kind":"exercise","acquired":false,"shares":6775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option shares vested and became exercisable in 12 monthly installments from October 9, 2014."}],"balance_after":0,"derivative":{"exercise_price":0.74,"expiration_date":"2025-01-12","underlying":"Common Stock","underlying_shares":6775},"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899290,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-20","kind":"exercise","acquired":false,"shares":3016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option shares vested and became exercisable in 12 monthly installments from October 9, 2013."}],"balance_after":0,"derivative":{"exercise_price":0.48,"expiration_date":"2024-01-27","underlying":"Common Stock","underlying_shares":3016},"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899289,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-21","kind":"sale","acquired":false,"shares":3799,"price":12,"value":45588.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 3,799 shares sold at $12.00 and $12.01 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":43181,"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899288,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-21","kind":"exercise","acquired":true,"shares":3799,"price":2.36,"value":8965.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":46980,"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899287,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-20","kind":"sale","acquired":false,"shares":10000,"price":10.03,"value":100300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $10.00 to $10.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":43181,"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899286,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-20","kind":"sale","acquired":false,"shares":16201,"price":12.03,"value":194898.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 16,201 shares sold in the price range of $12.00 to $12.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":53181,"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899285,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-20","kind":"exercise","acquired":true,"shares":3710,"price":2.36,"value":8755.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":69382,"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899284,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-20","kind":"exercise","acquired":true,"shares":6775,"price":0.74,"value":5013.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":65672,"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2899283,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-22T18:35:57.000Z","date":"2021-01-20","kind":"exercise","acquired":true,"shares":3016,"price":0.48,"value":1447.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":58897,"source":{"system":"sec-edgar","filing":"0001640455-21-000016","document":"wf-form4_161135854303039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000016/wf-form4_161135854303039.xml","form_type":"4"}},{"id":2910998,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-11T06:19:56.000Z","date":"2021-01-08","kind":"sale","acquired":false,"shares":3130,"price":7,"value":21910.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,130 shares sold in the price range of $6.75 to $7.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":55881,"source":{"system":"sec-edgar","filing":"0001640455-21-000008","document":"wf-form4_161036398211616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000008/wf-form4_161036398211616.xml","form_type":"4"}},{"id":2910997,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-11T06:19:56.000Z","date":"2021-01-07","kind":"sale","acquired":false,"shares":2697,"price":6.76,"value":18231.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 2,697 shares sold in the price range of $6.66 to $7.02 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":59011,"source":{"system":"sec-edgar","filing":"0001640455-21-000008","document":"wf-form4_161036398211616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000008/wf-form4_161036398211616.xml","form_type":"4"}},{"id":3041203,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2020-09-02T18:05:44.000Z","date":"2020-09-01","kind":"sale","acquired":false,"shares":7200,"price":8.06,"value":58032.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 7,200 shares sold in the price range of $8.00 to $8.10 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":61708,"source":{"system":"sec-edgar","filing":"0001640455-20-000114","document":"wf-form4_159908432700496.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000114/wf-form4_159908432700496.xml","form_type":"4"}},{"id":3054333,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2020-08-18T20:31:15.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":744,"price":4.71,"value":3504.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 744 shares sold in the price range of $4.67 to $4.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":68908,"source":{"system":"sec-edgar","filing":"0001640455-20-000109","document":"wf-form4_159779705956306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000109/wf-form4_159779705956306.xml","form_type":"4"}},{"id":3054332,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2020-08-18T20:31:15.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":454,"price":4.86,"value":2206.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 454 shares sold in the price range of $4.72 to $5.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":69652,"source":{"system":"sec-edgar","filing":"0001640455-20-000109","document":"wf-form4_159779705956306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000109/wf-form4_159779705956306.xml","form_type":"4"}},{"id":3054331,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2020-08-18T20:31:15.000Z","date":"2020-08-14","kind":"sale","acquired":false,"shares":984,"price":4.64,"value":4565.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 984 shares sold in the price range of $4.55 to $4.75 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":70106,"source":{"system":"sec-edgar","filing":"0001640455-20-000109","document":"wf-form4_159779705956306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000109/wf-form4_159779705956306.xml","form_type":"4"}},{"id":3095142,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-01T17:24:16.000Z","date":"2020-06-29","kind":"grant","acquired":true,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer."}],"balance_after":17400,"derivative":{"exercise_price":1.39,"expiration_date":"2030-06-29","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001209191-20-039822","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000120919120039822/doc4.xml","form_type":"4"}},{"id":3291798,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2020-02-04T21:00:19.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":53400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest quarterly in 16 equal installments following January 1, 2020."}],"balance_after":53400,"derivative":{"exercise_price":6.55,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":53400},"source":{"system":"sec-edgar","filing":"0001640455-20-000019","document":"wf-form4_158086800255339.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000019/wf-form4_158086800255339.xml","form_type":"4"}},{"id":3291797,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2020-02-04T21:00:19.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":26700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":71090,"source":{"system":"sec-edgar","filing":"0001640455-20-000019","document":"wf-form4_158086800255339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000019/wf-form4_158086800255339.xml","form_type":"4"}},{"id":3313643,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2020-01-10T08:54:12.000Z","date":"2020-01-07","kind":"sale","acquired":false,"shares":2624,"price":7.78,"value":20414.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 2,624 shares sold in the price range of $7.62 to $7.88 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":44390,"source":{"system":"sec-edgar","filing":"0001640455-20-000006","document":"wf-form4_157866443594759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000006/wf-form4_157866443594759.xml","form_type":"4"}},{"id":3436206,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2019-08-16T20:58:31.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":1018,"price":3.92,"value":3990.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 1,018 shares sold in the price range of $3.85 to $4.06 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":47014,"source":{"system":"sec-edgar","filing":"0001640455-19-000075","document":"wf-form4_156600349377656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045519000075/wf-form4_156600349377656.xml","form_type":"4"}},{"id":3436205,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2019-08-16T20:58:31.000Z","date":"2019-08-15","kind":"sale","acquired":false,"shares":648,"price":4,"value":2592.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 648 shares sold in the price range of $3.94 to $4.09 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":48032,"source":{"system":"sec-edgar","filing":"0001640455-19-000075","document":"wf-form4_156600349377656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045519000075/wf-form4_156600349377656.xml","form_type":"4"}},{"id":3436204,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2019-08-16T20:58:31.000Z","date":"2019-08-14","kind":"sale","acquired":false,"shares":670,"price":4.1,"value":2747.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 670 shares sold in the price range of $4.02 to $4.18 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":48680,"source":{"system":"sec-edgar","filing":"0001640455-19-000075","document":"wf-form4_156600349377656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045519000075/wf-form4_156600349377656.xml","form_type":"4"}},{"id":3674148,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T21:25:43.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":30600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities shall vest and become exercisable in equal quarterly installments starting on May 1, 2019 until the option is fully vested and exercisable on February 1, 2020, subject to continued service."}],"balance_after":30600,"derivative":{"exercise_price":3,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":30600},"source":{"system":"sec-edgar","filing":"0001209191-19-007619","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000120919119007619/doc4.xml","form_type":"4"}},{"id":3674376,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T18:02:04.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":44500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest quarterly in 16 equal installments following January 1, 2019."}],"balance_after":44500,"derivative":{"exercise_price":4.4,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":44500},"source":{"system":"sec-edgar","filing":"0001640455-19-000010","document":"wf-form4_154940770860401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045519000010/wf-form4_154940770860401.xml","form_type":"4"}},{"id":3674375,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2019-02-05T18:02:04.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":22250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":49350,"source":{"system":"sec-edgar","filing":"0001640455-19-000010","document":"wf-form4_154940770860401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045519000010/wf-form4_154940770860401.xml","form_type":"4"}},{"id":3831618,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-28T17:28:28.000Z","date":"2018-08-27","kind":"exercise","acquired":false,"shares":12700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter."}],"balance_after":213514,"derivative":{"exercise_price":2.36,"expiration_date":"2025-08-25","underlying":"Common Stock","underlying_shares":12700},"source":{"system":"sec-edgar","filing":"0001640455-18-000103","document":"wf-form4_153549169199929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000103/wf-form4_153549169199929.xml","form_type":"4"}},{"id":3831617,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2018-08-28T17:28:28.000Z","date":"2018-08-27","kind":"exercise","acquired":true,"shares":12700,"price":2.36,"value":29972.0,"ownership":{"direct":true},"balance_after":27100,"source":{"system":"sec-edgar","filing":"0001640455-18-000103","document":"wf-form4_153549169199929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000103/wf-form4_153549169199929.xml","form_type":"4"}},{"id":3843336,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2018-08-15T17:27:25.000Z","date":"2018-08-13","kind":"grant","acquired":true,"shares":14400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14400,"source":{"system":"sec-edgar","filing":"0001640455-18-000099","document":"wf-form4_153436842609305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000099/wf-form4_153436842609305.xml","form_type":"4"}},{"id":4001118,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-12T19:06:07.000Z","date":"2018-03-08","kind":"exercise","acquired":false,"shares":3759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shares vested and became exercisable in 12 monthly installments from October 9, 2013."}],"balance_after":3016,"derivative":{"exercise_price":0.48,"expiration_date":"2024-01-27","underlying":"Common Stock","underlying_shares":3759},"source":{"system":"sec-edgar","filing":"0001640455-18-000039","document":"wf-form4_152089594368204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000039/wf-form4_152089594368204.xml","form_type":"4"}},{"id":4001117,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2018-03-12T19:06:07.000Z","date":"2018-03-08","kind":"sale","acquired":false,"shares":5267,"price":25.01,"value":131727.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 5,267 shares sold in the price range of $25.00 to $25.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001640455-18-000039","document":"wf-form4_152089594368204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000039/wf-form4_152089594368204.xml","form_type":"4"}},{"id":4001116,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2018-03-12T19:06:07.000Z","date":"2018-03-08","kind":"exercise","acquired":true,"shares":3759,"price":0.48,"value":1804.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions."}],"balance_after":5267,"source":{"system":"sec-edgar","filing":"0001640455-18-000039","document":"wf-form4_152089594368204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000039/wf-form4_152089594368204.xml","form_type":"4"}},{"id":4008348,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2018-03-07T18:57:57.000Z","date":"2018-03-05","kind":"sale","acquired":false,"shares":1267,"price":22.07,"value":27962.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 1,267 shares sold in the price range of $21.89 to $22.20 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":1508,"source":{"system":"sec-edgar","filing":"0001640455-18-000022","document":"wf-form4_152046705270757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000022/wf-form4_152046705270757.xml","form_type":"4"}},{"id":4008347,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2018-03-07T18:57:57.000Z","date":"2018-03-05","kind":"sale","acquired":false,"shares":4000,"price":21.21,"value":84840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 4,000 shares sold in the price range of $20.89 to $21.86 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2775,"source":{"system":"sec-edgar","filing":"0001640455-18-000022","document":"wf-form4_152046705270757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000022/wf-form4_152046705270757.xml","form_type":"4"}},{"id":4076369,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-05T18:05:30.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":97500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest quarterly in 16 equal installments following January 1, 2018."}],"balance_after":97500,"derivative":{"exercise_price":23.98,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":97500},"source":{"system":"sec-edgar","filing":"0001640455-18-000013","document":"wf-form4_151787191594300.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000013/wf-form4_151787191594300.xml","form_type":"4"}}]}